Drug Discovery
ByIs Insilico Medicine Redefining Drug Discovery as AI Becomes Core to Biopharma Strategy?
Executive Summary Insilico Medicine has emerged as one of the most influential AI-native biotechnology companies, reshaping how the…
Can Vanda Pharma’s FDA Approval of Nereus Unlock a New Growth Chapter in Motion-Sickness Treatment?
New York | Jan, 2026 — Vanda Pharmaceuticals Inc. achieved a major regulatory and commercial milestone after the…
Can Bristol Myers Squibb’s $330 Million AI Investment in 2025 — Powered by Strategic Partnerships — Accelerate Discovery, R&D and Commercial Impact in 2026?
Global – December 31, 2025 — Bristol Myers Squibb (BMS) significantly expanded its commitment to artificial intelligence (AI)…
Can GSK’s $340 Million AI Investment in 2025 — Backed by Strategic Collaborations — Accelerate Discovery, R&D and Commercial Growth in 2026?
Global – December 31, 2025 — GlaxoSmithKline plc (GSK) significantly expanded its use of artificial intelligence (AI) throughout…
Is Regional Distribution Becoming a Strategic Lever for Big Pharma? Novartis Expands European Reach Through Malta Partnership
23 January 2026 Executive Summary Novartis Pharma Services AG has entered into a strategic distribution agreement with Vivian…
Can Localized Manufacturing Shield Big Pharma from Trade Volatility? Novartis Targets Zero U.S. Tariff Exposure by Mid-2026
23 January 2026 Executive Summary Novartis CEO Vas Narasimhan has outlined a decisive trade-risk mitigation strategy, stating that…
